

Table of Contents

Preface	v	4	Different products and their supply chain	35
List of abbreviations.....	xiii			
1 The history of cannabis	1	4.1	Cultivation and processing of the drug	35
1.1 Cannabis in ancient times.....	1	4.1.1	Cannabis physiology	35
1.2 Hemp in the Middle Ages.....	1	4.1.2	Standardized and quality assured cannabis flowers.....	36
1.3 Cannabis in 19th century European mainstream medicine	4	4.1.3	Plant genetic resourcesand propagation	37
1.3.1 Indian hemp arrives in Europe	4	4.1.4	Outdoor cultivation	38
1.3.2 A momentous study	4	4.1.5	Greenhouse cultivation	39
1.3.3 Cannabis becomes established	5	4.1.6	Indoor cultivation	40
1.3.4 First peak in the 19th century.....	6	4.1.7	Harvest and post-harvest methods	41
1.4 Cannabis as a medicinal substance in the 20th century.....	7	4.1.8	Comparison of cultivation systems.....	43
1.4.1 The end of an era	7	4.2	Quality standards.....	46
1.4.2 The Renaissance	7	4.2.1	Differentiation of substances, preparations and medicinal products.....	46
1.4.3 From Opium Law to Cannabis Law in Germany	8	4.2.2	Quality assurance	49
1.5 Cannabis as a treatment option in the 21st century	8	4.2.3	Quality requirements for cannabis flowers	55
2 Botanical description	10	4.2.4	Quality requirements for preparations from cannabis flowers	64
2.1 Systematics and Taxonomy	10	4.2.5	Specific requirements for isolated cannabins as active ingredients in medicinal products	68
2.2 General botanical characteristics	11	4.2.6	Quality requirements for cannabis-based medicinal products	71
2.2.1 Habitus, sprout and sex distribution.....	11	4.2.7	Stability studies	72
2.2.2 Inflorescences and flowers	13	4.2.8	Regulatory aspects of quality control	73
2.2.3 Fruits	15	4.3	Production of cannabis extracts	75
2.3 Cannabis breeding and current cultivars	16	4.3.1	Pre- and post-treatment during extraction ..	75
3 Biosynthetic pathways of the cannabinoids	18	4.3.2	Extraction with ethanol	76
3.1 Cannabinoids.....	18	4.3.3	Extraction with hydrocarbons	76
3.1.1 Cannabinoids as chemotaxonomic markers ..	18	4.3.4	Extraction with supercritical carbon dioxide.....	76
3.1.2 Cannabinoid biosynthesis	18	4.3.5	Isolation of pure cannabinoids.....	77
3.1.3 Artificial enzymatic production of cannabinoids	23	4.3.6	Development of the extraction process.....	78
3.1.4 Chemical synthesis and properties of cannabidiol (CBD).....	26	4.3.7	Validation of the extraction process.....	79
3.1.5 Chemical synthesis and properties of Δ^9 -tetrahydrocannabinol (Δ^9 -THC).....	26	4.4	Special considerations for clinical investigational medicinal products	80
3.1.6 Chemical synthesis and properties of nabilone.....	28	4.5	Biotechnological production of cannabinoids.....	80
3.2 Terpenes	30	4.5.1	Motivation.....	80
3.3 Other secondary substances	31	4.5.2	Metabolic engineering.....	81
3.4 Chemotypes of <i>Cannabis sativa</i>	32	4.5.3	Challenges for the future	83
		5	Supply of medical cannabis	87
		5.1	Import from EU and non-EU countries.....	87
		5.1.1	Requirements for import	87
		5.1.2	Permit and documentation requirements	88
		5.1.3	Organizational processing.....	90

5.2	Cultivation in Germany	92	7.5	Neurodegenerative, neuroinflammatory and other neurological diseases	144
5.2.1	Prerequisites and legal framework	92	7.5.1	Spasticity and paraplegia	144
5.2.2	Quality-related requirements for the cultivation of medical cannabis in Germany	93	7.5.2	Spasticity in multiple sclerosis	144
6	Pharmacological basis of cannabinoid action	94	7.5.3	Huntington's chorea	144
6.1	The endocannabinoid system	94	7.5.4	Epilepsy	147
6.1.1	What is the endocannabinoid system?	94	7.5.5	Dystonia	148
6.1.2	Physiology	94	7.5.6	Parkinson's disease	148
6.1.3	Disorders of the endocannabinoid system	97	7.6	Ophthalmological diseases	150
6.1.4	Cannabinoid (CB) receptors	98	7.6.1	Glaucoma	150
6.1.5	Ligands	100	7.6.2	Uveitis	151
6.1.6	Biological and biographical differences	105	7.6.3	Dry eye	151
6.2	Pharmacokinetics and pharmacodynamics of THC and CBD	110	7.7	Psychiatric disorders	152
6.2.1	THC	110	7.7.1	Dementia	152
6.2.2	Cannabidiol (CBD)	113	7.7.2	Gilles de la Tourette syndrome	156
6.3	Entourage effect	115	7.7.3	ADHD	159
6.3.1	Entourage effect in the ECS	115	7.7.4	Obsessive compulsive disorder	160
6.3.2	Entourage effect due to secondary cannabis ingredients	116	7.7.5	Anxiety disorders	161
7	Medical applications and their evidence	120	7.7.6	Affective disorders	163
7.1	General information on dosage and dose finding	120	7.7.7	Post-traumatic stress disorder	164
7.1.1	Start of treatment	120	7.7.8	Psychosis	165
7.1.2	Type of use	121	7.7.9	Autism spectrum disorder	166
7.1.3	Dosage titration	122	7.8	Skin disorders	172
7.1.4	Application frequency and distribution throughout the day	122	7.8.1	Endocannabinoid system of the skin	173
7.2	Chronic pain	123	7.8.2	Wound treatment	175
7.2.1	Preclinical findings	123	7.8.3	Modulation of the skin barrier	176
7.2.2	Clinical findings and evidence	124	7.8.4	Atopic dermatitis	176
7.2.3	Dosage	128	7.8.5	Pruritus	178
7.2.4	Tolerability and safety	129	7.8.6	Allergic contact dermatitis (ACD)	178
7.3	Nausea, vomiting, appetite stimulation	132	7.8.7	Acne vulgaris	179
7.3.1	Definitions	132	7.8.8	Epidermolysis bullosa (EB)	179
7.3.2	Hypothesis of mechanism of action for cannabinoids	132	7.8.9	Pyoderma gangrenosum	179
7.3.3	Nausea and vomiting	132	7.8.10	Psoriasis	180
7.3.4	Appetite stimulation and cachexia	133	7.8.11	Skin cancer	180
7.3.5	Conclusion	134	7.8.12	Conclusion	181
7.4	Gastroenterological diseases	135	8	Cannabis as a stimulant	185
7.4.1	Inflammatory bowel disease (Crohn's disease and ulcerative colitis)	135	8.1	Model projects on cannabis	185
7.4.2	Irritable Bowel Syndrome	137	8.1.1	Application from Berlin	185
			8.1.2	Application from Schleswig-Holstein	185
			8.1.3	Renewed application from Berlin	186
			8.2	Consequences of cannabis use	187
			8.2.1	Cannabis intoxication	187
			8.2.2	Abuse, dependence, concomitant use, scene entry	187
			8.2.3	Other cannabis-related disorders	190
			8.2.4	Trigger factors and consequences of legalization	193

8.3	Comparison to other stimulants and addictive substances (alcohol, caffeine, nicotine, heroin etc.)	198	10.2	Regulatory framework at European level	230
8.3.1	Alcohol	198	10.2.1	Possibilities for placing on the market on the basis of a formal authorization	231
8.3.2	Nicotine (smoking)	200	10.2.2	Possibilities for placing on the market without formal authorization	231
8.3.3	Heroin	201	10.3	Legal basis and availability of cannabis abroad (EU, non-EU)	232
8.3.4	Comparison with cannabis	202	10.3.1	The Netherlands	232
9	Risks associated with the medical use of cannabis	205	10.3.2	Italy	232
9.1	Adverse drug reactions (ADRs)	205	10.3.3	United Kingdom	233
9.1.1	THC and other CB1 agonists	205	10.3.4	Denmark	233
9.1.2	CBD	209	10.3.5	Israel	233
9.1.3	Extracts and flowers	210	10.3.6	Canada	234
9.2	Interactions with cannabinoids	212	10.3.7	Australia	234
9.2.1	THC and other CB1 agonists	212	10.3.8	Columbia	235
9.2.2	CBD	213	10.3.9	United States of America	235
9.2.3	Interactions between CBD and THC	213	10.4	Legal framework in Germany	237
9.2.4	Extracts and flowers	214	10.4.1	Narcotics Act (Betäubungsmittelgesetz, BtMG)	237
9.2.5	Pharmacology-based guidance on the safe use of cannabis-based medicinal products	214	10.4.2	Narcotics Foreign Trade Ordinance (Betäubungsmittel-Außenhandelsverordnung, BtMAHV)	238
9.3	Contraindications	215	10.4.3	Narcotics Prescription Ordinance (Betäubungsmittel-Verschreibungsverordnung, BtMVV)	238
9.3.1	THC and other CB1 agonists	215	10.4.4	Fifth Book of the German Social Code (SGB V)	239
9.3.2	CBD	216	10.5	Structure and function of the Cannabis Agency	239
9.4	Tolerance and addiction or dependence	217	10.5.1	Legal basis	239
9.4.1	THC and other CB1 agonists	217	10.5.2	Development of the Cannabis Agency	240
9.4.2	CBD	218	10.5.3	Responsibilities and monitoring	241
9.5	Impairment of driving safety	218	10.6	Authorization for medical use	242
9.5.1	Pharmacokinetics	219	10.6.1	(Social) medical requirements	242
9.5.2	Effects relevant for traffic	219	10.6.2	Documents required	244
9.5.3	Analytical methods for detection of cannabinoids in biological material and their interpretation	220	10.6.3	Course of the approval procedure	244
9.5.4	Legal regulations	221	10.6.4	Conclusion	246
9.5.5	Penalty thresholds in international comparison	221	10.7	Companion survey/scientific project	247
9.5.6	Prevalence and risk identification	222	11	Legal status of medicinal cannabis and cannabinoids in Germany	252
9.5.7	Outlook	223	11.1	Definitions of terms: active substance, medicinal product, proprietary medicinal product	252
10	Legal framework for the use of cannabis	225	11.2	Cannabis-based proprietary medicinal products	253
10.1	International agreements	225	11.3	Cannabis-based prescription drugs	254
10.1.1	Single Convention on Narcotic Drugs, 1961	227			
10.1.2	Convention on Psychotropic Substances, 1971	228			
10.1.3	United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988	229			

12	Legal status of cannabis and cannabinoids in non-medicinal products	256	13.8.3	Ready-to-use cannabis-based medicinal products authorized in Switzerland	293
12.1	CBD and cannabis preparations in foodstuffs and nutritional supplements	256	13.9	United Kingdom	295
12.1.1	Food	256	13.9.1	Medical cannabis	295
12.1.2	Food supplements	260	13.9.2	CBD consumer products	297
12.1.3	Flavorings	262	14	Forms and methods of administration	300
12.1.4	CBD products as medicinal products by function or presentation	262	14.1	Dosage forms for medical use	300
12.2	CBD and cannabis preparations in medical devices	265	14.1.1	Tablets	300
12.3	CBD and cannabis preparations in cosmetics	266	14.1.2	Capsules	302
12.4	CBD and cannabis preparations in smoking products	267	14.1.3	Decoctions („tea“)	302
13	Medicinal Cannabis: Case studies from selected European countries	269	14.1.4	Oil	304
13.1	Czech Republic	269	14.1.5	Oromucosal spray	310
13.2	France	270	14.1.6	Inhalants	311
13.2.1	Beginnings	270	14.1.7	Suppositories	318
13.2.2	Main objectives	272	14.1.8	Transdermal therapeutic systems and semi-solid dermatics	320
13.2.3	Experimental framework	272	14.1.9	Parenterals	320
13.2.4	Patients' involvement	272	14.1.10	Eyedrops	321
13.2.5	Category of medications offered to patients within the scope of the study	273	14.1.11	Edibles	322
13.2.6	Call for applications	273	14.2	Forms of consumption in recreational use .	331
13.2.7	Selected suppliers	275	14.2.1	Marijuana	335
13.2.8	Approved medications	275	14.2.2	Solventless concentrates	336
13.2.9	Supply and distribution	276	14.2.3	Solvent-using concentrates	340
13.3	Greece	279	14.2.4	Cannabis tinctures	343
13.4	Italy	280	14.2.5	Foods containing cannabis	344
13.5	Malta	281	14.2.6	Synthetic cannabinoids	346
13.6	Poland	282	14.3	Types of administration in recreational use	348
13.6.1	Magistral preparations	283	14.3.1	Joints, spliffs and blunts	349
13.6.2	Compounding	284	14.3.2	Chillums, one-hitters, pipes	351
13.6.3	Pharmaceutical raw material	285	14.3.3	Hookahs and bongs	351
13.6.4	Dosage forms of magistral preparations	285	14.3.4	Bucket smoking	353
13.6.5	Extemporaneous medicine of medical cannabis in Poland	286	14.3.5	Hot knives (spots)	354
13.7	Portugal	287	14.3.6	Glass smoking or hot needles	354
13.8	Switzerland	290	14.3.7	Vaping	354
13.8.1	Legal framework	290	14.3.8	Dabbing	356
13.8.2	Authorization procedures in Switzerland	292	15	Compounding of medicinal products containing cannabinoids in the pharmacy	358
			15.1	Legal framework	358
			15.1.1	Magistral preparations (Rezepturarzney-mittel)	358
			15.1.2	Officinal medicinal product (Defektur-arzneimittel)	358
			15.2	Manufacturing documentation	360
			15.2.1	Manufacturing instructions	360
			15.2.2	Manufacturing protocol	361

15.3 Starting material testing	361	15.8.2 Specifics of cannabis price calculation	445
15.3.1 Legal framework and testing obligations	361	15.8.3 Rounding rules for price calculation	447
15.3.2 Starting materials without a certificate of analysis	361	15.8.4 Special PZN for magistral preparations containing cannabinoids	447
15.3.3 Starting materials with a certificate of analysis	362	15.8.5 Determining the most economical package or package size combination	448
15.3.4 Test methods	364	15.8.6 Imported cannabis flowers in unchanged form	448
15.3.5 Documentation obligation	364	15.8.7 Imported cannabis flowers in preparations ..	448
15.4 Available starting materials and sources of supply	364	15.8.8 Cannabis flowers from German cultivation	450
15.4.1 Flowers	364	15.8.9 Cannabis extracts in unchanged state	450
15.4.2 Extracts	365	15.8.10 Cannabis extracts in preparations	451
15.4.3 Cannabinoids	372	15.8.11 Dronabinol in preparations	451
15.4.4 Special characteristics of manufacturing sets	373	15.8.12 Cannabidiol in preparations	451
15.5 Testing of starting materials for cannabis flowers, cannabis extracts and cannabinoids	374	16 Supply of cannabis prescriptions in the pharmacy	458
15.5.1 Cannabis flowers	374	16.1 Legal framework	458
15.5.2 Extracts	383	16.1.1 General formalities of the regulation of narcotics	458
15.5.3 Dronabinol	384	16.1.2 Maximum quantities in the prescription of cannabis medicinal products	459
15.5.4 CBD	390	16.1.3 Specific features of the prescription of cannabis medicinal products	459
15.5.5 Combined test systems discriminating THC or CBD-dominant and equilibrated starting materials	394	16.1.4 Prescription drugs	465
15.6 Manufacture of magistral preparations	399	16.1.5 Proprietary medicinal products	465
15.6.1 Weighing correction	400	16.1.6 Non-availability	468
15.6.2 Plausibility check	403	16.1.7 Drug substitution in cannabis preparations ..	468
15.6.3 Important processing aspects for standardized cannabis formulations	409	16.1.8 Discount agreements for cannabis medicinal products	470
15.6.4 Child-resistant packaging	420	16.1.9 Obligation to check for cost coverage by statutory health insurance	471
15.6.5 Baking mixtures	421	16.1.10 Individual imports in accordance with Section 73(3) of the German Medicinal Products Act	471
15.6.6 Production of flower or extract mixtures with defined THC and CBD contents	424	16.2 Special features of pharmacy logistics when handling medicinal products containing cannabis	472
15.7 Preparation of officinal medicinal products	431	16.2.1 Storage	472
15.7.1 Test instructions for officinal medicinal products	431	16.2.2 Cannabis in mail order and courier service	473
15.7.2 Test protocol for officinal medicinal products	431	16.2.3 Transfer of narcotic drugs containing cannabinoids between pharmacies	474
15.7.3 Risk-based tiered model for final analytical testing	432	16.2.4 Returns of narcotics containing cannabinoids	475
15.7.4 Application of the risk-based tiered model to medicinal products containing cannabis or cannabinoids	435	16.2.5 Dealing with quality defects	475
15.8 Price calculation	445	16.2.6 Withdrawal of narcotics containing cannabinoids by pharmacies	476
15.8.1 Basic principles of price calculation for compounded preparations	445	16.2.7 Destruction of narcotics containing cannabinoids	476

17	Narcotics documentation	479	17.3.6 Prescription of cannabis-based proprietary medicinal products	493	
17.1	Legal basis.....	479	18	Important considerations for counseling cannabis patients	498
17.2	General documentation requirements for narcotics	479	18.1	General instructions for use.....	498
17.2.1	Import and export of narcotics (Section 11 of the Narcotics Act)	480	18.2	Instructions for use specific to the dosage form or mode of administration	498
17.2.2	Dispensing and acquisition of narcotics (Section 12 of the Narcotics Act)	480	18.3	Vaporization	498
17.2.3	Dispensing narcotics on the basis of a prescription (Section 13 of the Narcotics Act).....	482	18.3.1	Filling dosing capsules.....	498
17.2.4	Labeling according to Section 17 of the Narcotics Act and Section 14 of the Ordinance on the Prescription of Narcotics	483	18.3.2	Volcano Medic 2	500
17.2.5	Destruction of narcotics according to Section 16 of the Narcotics Act	484	18.3.3	Mighty Medic or Mighty+ Medic.....	500
17.2.6	Reporting according to Section 18 of the Narcotics Act	484	18.4	Dosing	501
17.3	Special features of narcotics documentation for prescription medicinal products containing cannabis.....	485	18.5	Cannabis patients and driving.....	505
17.3.1	Narcotics documentation specific to variety/extract.....	485	18.6	Traveling with cannabis	506
17.3.2	Formulation production and documentation	487	18.6.1	Traveling within the Schengen area	506
17.3.3	Excess consumption	489	18.6.2	Traveling outside the Schengen area	506
17.3.4	Weighing gain, weighing loss and overfill.....	492	18.6.3	Carrying of cannabis medicinal products by physicians.....	509
17.3.5	Mishaps during production	492	18.7	Hunting license	509
			18.8	Recognizing abuse and dealing with suspected misuse	509
			Photo credits	513	
			Subject index	517	
			The editor	535	
			The authors	536	